Disparities in neoadjuvant chemotherapy for pancreatic adenocarcinoma with vascular involvement
{{output}}
Background: Multiagent neoadjuvant chemotherapy (NAT) has been linked with improved survival for locally advanced (LA) or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). However, the existence of disparities i... ...
